[DISCLOSURE]
Yuhan Corp. (000100) announced on July 28 that it has signed a technology transfer deal with China’s Luoxin Biotechonology for YH25448, a new targeted therapy for lung cancer.
The firm will receive an upfront payment of US$6 million and subsequent milestone payments that amount up to US$120 million.
